Scarica l'app Stockscreener
1.85
6.57%
-0.13
Dopo l'orario di chiusura:
1.85
Precedente Chiudi:
$1.98
Aprire:
$1.98
Volume 24 ore:
138.02K
Relative Volume:
0.57
Capitalizzazione di mercato:
$137.53M
Reddito:
-
Utile/perdita netta:
$-19.57M
Rapporto P/E:
-0.5911
EPS:
-3.13
Flusso di cassa netto:
$-17.24M
1 W Prestazione:
-2.63%
1M Prestazione:
+11.45%
6M Prestazione:
-34.16%
1 anno Prestazione:
+12.80%
Intervallo 1D:
$1.80
$1.99
Intervallo di 1 settimana:
$1.80
$1.995
Portata 52W:
$1.12
$4.20
Inhibikase Therapeutics Inc Stock (IKT) Company Profile
Nome
Inhibikase Therapeutics Inc
Settore
Industria
Telefono
678-392-3419
Indirizzo
3350 RIVERWOOD PARKWAY SE, SUITE 1900, ATLANTA
Confronta IKT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IKT
Inhibikase Therapeutics Inc
|
1.85 | 147.20M | 0 | -19.57M | -17.24M | -3.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Inhibikase Therapeutics Inc Stock (IKT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-12 | Downgrade | H.C. Wainwright | Buy → Neutral |
Inhibikase Therapeutics Inc Borsa (IKT) Ultime notizie
What drives Inhibikase Therapeutics Inc. stock priceConsistently high yield - Autocar Professional
How high can Inhibikase Therapeutics Inc. stock price go in 2025Rapid profit acceleration - jammulinksnews.com
Inhibikase Therapeutics Inc. Stock Analysis and ForecastUnrivaled growth potential - Autocar Professional
Is Inhibikase Therapeutics Inc. a good long term investmentPhenomenal investment performance - Autocar Professional
What analysts say about Inhibikase Therapeutics Inc. stockBreakout profit opportunities - Autocar Professional
What analysts say about Tianci International Inc. stockTriple-digit profit margins - jammulinksnews.com
How Inhibikase Therapeutics Inc. stock performs during market volatilityMarket Beating Strategy - Newser
What makes Inhibikase Therapeutics Inc. stock price move sharplyVolume Spike Monitors - Newser
What risks could impact Inhibikase Therapeutics Inc. stock performance2x Return Forecast - Newser
Why Inhibikase Therapeutics Inc. stock attracts strong analyst attentionSmart High Yield Swing Trades - beatles.ru
Inhibikase Therapeutics Approves Key Proposals at Annual Meeting - The Globe and Mail
Inhibikase Therapeutics shareholders elect directors and approve equity plan changes - Investing.com India
Inhibikase Therapeutics Soars 6.79% on Russell 2000 Index Addition - AInvest
Inhibikase Therapeutics, Inc.(NasdaqCM: IKT) added to Russell 2500 Index - MarketScreener
IKT SEC FilingsInhibikase Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Ludwig Enterprises appoints Garth Lees-Rolfe as independent director By Investing.com - Investing.com UK
Squarepoint Ops LLC Acquires Shares of 28,411 Inhibikase Therapeutics, Inc. (NYSE:IKT) - Defense World
Millennium Management LLC Invests $462,000 in Inhibikase Therapeutics, Inc. (NYSE:IKT) - Defense World
Northern Trust Corp Invests $208,000 in Inhibikase Therapeutics, Inc. (NYSE:IKT) - Defense World
Inhibikase Therapeutics Insider Buyers Pleased With US$788k Return On Investment - simplywall.st
Inhibikase Therapeutics Reports Q1 2025 Financial Results - TipRanks
13,129 Shares in Inhibikase Therapeutics, Inc. (NYSE:IKT) Purchased by Stifel Financial Corp - Defense World
Inhibikase Therapeutics: Strategic Realignment and Financial Strength Justify Buy Rating - TipRanks
Inhibikase Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Inhibikase Therapeutics Inc Azioni (IKT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.32%
1.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):